The Symposium consists of three keynote addresses and four platform presentations by the following individuals, with allotted time for questions and answers after each presentation. 
selection of optimum clinical and biological markers without which neuroprotective drug effects cannot be detected. Methods: The HD Toolkit project utilizes the principles of evidence-based medicine to guide systematic review and metaanalysis of measurement tools extracted from published articles (Ͼ10,000) and unpublished sources. Findings from the metaanalysis are integrated with advice from expert consultants and pragmatic issues to make recommendations for measurement selection in studies of pre-diagnostic and early HD. Results: Meta-analysis of more than 300 clinical markers has yielded several tests with clear evidence of sensitivity or insensitivity in pre-diagnostic and early HD. Cognitive and psychomotor tests with demonstrated sensitivity include Trails-B, Stroop Word, University of Pennsylvania Smell Identification Test, and speeded finger tapping. Tests with demonstrated longitudinal insensitivity in pre-diagnostic HD include Stroop Interference and Letter Fluency. A secondary function of the HD Toolkit is to identify promising measures that have yet to be adequately vetted in pre-diagnostic and early HD, and to promote investigation of these measures. Promising measures include gait analysis, kinematic drawing analysis, and visual perspective-taking tasks.
Conclusions:
In preparation for clinical trials, the HD Toolkit project offers no-cost consultation (website under development) providing an evidence-based resource for selecting and analyzing outcome measures with detectable sensitivity to early disease progression in HD.
hemoglobin, plasma glutamine, histone acetylation and gene expression in lymphocytes, plasma levels of phenylbutyrate and metabolites, and metabolomic profiling. Results: Phenylbutyrate was safe and well tolerated in early symptomatic HD subjects taking 15 grams daily. In the doubleblind phase, neither subjects nor investigators correctly predicted whether the compound was active or a placebo. Levels of phenylbutyrate and metabolites were measurable in blood as well as leukocyte histone acetylation, a pharmacodynamic biomarker of HDAC inhibition that responded to treatment. Conclusions: Fifteen grams daily of phenylbutyrate is safe and well tolerated and results in PK/PD responses supportive of further clinical development. Our data illuminate possible biomarkers for this and other HDAC inhibitors. Background: Ethyl-eicosapentaenoic acid (ethyl-EPA), an omega-3 fatty acid, was not an effective treatment for Huntington disease at 2 grams daily in the primary 6-month doubleblind study. Participants who completed the double-blind phase were given the opportunity to take open-label ethyl-EPA 2 grams daily for the following 6 months. Aim: To assess the efficacy of ethyl-EPA over 12 months. Methods: We conducted a multicenter, randomized, doubleblind, placebo-controlled trial in North America of ethyl-EPA (1 gram twice daily) for 6 months followed by a 6-month open-label study. The prespecified primary outcome measure was the change in the Total Motor Score 4 (TMS-4) component of the Unified Huntington's Disease Rating Scale. We restricted analysis of the 12-month results to those study participants who completed the open-label phase before April 24, 2007, when results of the primary analysis indicating no therapeutic benefit of ethyl-EPA in the study's 6-month doubleblind portion were released. Results: Of the 316 individuals enrolled in the 12-month study, 190 completed the open-label study before April 24, 2007. Their baseline features were generally similar to the whole study population. At 12 months, the TMS-4 change for those who were originally randomized to ethyl-EPA was significantly better than for those who were originally randomized to placebo (0.0 point change versus 1.8 point worsening; P ϭ 0.02), especially for those with a CAG repeat less than 45 (1.2 point improvement versus 1.6 point worsening; P ϭ 0.004). Differences favoring 12 months of continuous ethyl-EPA were also found on chorea but not on measures of global improvement, function, or cognition. Conclusions: Motor features of participants receiving ethyl-EPA for 12-months were improved compared with those receiving placebo for 6 months followed by ethyl-EPA for 6 months. In view of the negative results at 6 months, these findings require confirmation in longer term, controlled studies of ethyl-EPA. Objective: To report a case of SCA2 mimicking juvenile HD. Background: SCA2 has been reported to present with a widely varying clinical phenotype. Some descriptions in the literature include juvenile-onset parkinsonism, dystonia, chorea, and impaired oculomotor function. Methods: Case report. Results: A 13-year-old girl, with a reported family history of HD, presented for evaluation at our HD clinic. The patient's mother was reported to have HD beginning at age 20 during her first pregnancy; she was placed in a nursing home in her early 30s and died at age 42. Other affected family members include one of two siblings, a maternal aunt, grandmother, great-uncle, great-grandmother, and great-great-grandfather. The patient was doing well in eighth grade. One year prior she had undergone an elective 2nd trimester abortion following an unplanned pregnancy. During her pregnancy it was noted that she began slurring her words and had episodes of poor coordination, occasionally resulting in falls. Neurological examination revealed mildly impaired rapid alternating movements, impaired Luria, and dysarthria. Over the subsequent 8 years, there was a gradual progression of her symptoms, with severely slowed ocular saccades, worsening dysarthria, parkinsonism, mild generalized chorea, dystonia, postural instability, and behavioral changes marked by anger, irritability, and social withdrawal. Neuropsychological testing at age 18 revealed average general cognitive functioning, with significant difficulties in the domains of attention and executive functioning. Recent follow-up by phone revealed that the patient's affected brother tested positive for SCA2, and HD genetic testing in the patient was negative (15 and 18 CAG repeats).
The SCA2 mutation can produce a clinical phenotype that mimics juvenile HD. The case presented here was notable for the lack of cerebellar findings such as ataxia. In patients presenting with a juvenile HD phenotype, SCA2 should be considered in the differential diagnosis. Objective: To evaluate occurrence and degree of dystonia in relation to long-term treatment with olanzapine and risperidone, for the control of motor and psychiatric symptoms of Huntington's disease. Background: Dystonia in adult-onset HD increases as the disease progresses. Olanzapine and risperidone have been found to induce both focal and generalized dystonias. Atypical neuroleptics may induce early onset dystonia, which may accelerate functional decline. Methods and Results: A retrospective analysis of medical records from 64 Huntington's disease patients was performed. Patients included those treated with olanzapine (n ϭ 23, average age 53.3 years), risperidone (n ϭ 18, average age 46.2 years), or nothing (n ϭ 23, average age 51.4 years). All but 4 patients had genetically confirmed HD, with an average CAG repeat length of 44.4 for all patients.
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Dystonia was assessed by reviewing Unified Huntington's Disease Rating Scale records and written reports from two examiners. Occurrence and severity of dystonia were deter-mined in five body regions with a 0 -4 rating as set forth in the UHDRS. Total dystonia was the sum of scores observed in each body region (range 0 -20). Average disease duration was 8.1, 11.5, and 10.1 years for control, olanzapine, and risperidone groups, respectively. There was a modest positive correlation (r ϭ 0.22) between disease duration and average dystonia score across all patients.
Mean dose of olanzapine and risperidone were 8.9 mg/day (range 2.5-30 mg/day) and 2.4 mg/day (range 0.5-5 mg/day), respectively, over an average treatment duration of 2.9 years for all groups (range 0 -8 years). Dystonia scores averaged 2.1, 4.0, and 2.8 for the control, olanzapine-treated, and risperidonetreated groups, respectively, over the treatment period, but no significant differences were found in dystonia scores between groups using mixed effects modeling. Conclusions: Use of olanzapine and risperidone at common dosages to treat motor and psychiatric symptoms of Huntington's disease does not significantly alter occurrence or severity of dystonia. Baseline and last observation UHDRS motor scores (total motor, chorea and bradykinesia subscore) and weight were analyzed using a mixed factor ANOVA with clinical site as the between-subjects variable and baseline/after treatment as the within-subjects variable. Alpha was set to 0.05. Results: There were 41 patients (17 male). Mean age was 50 years, duration of HD was 9.4 years; TFC was 6, and (CAG)n was 45. The clinical indication for treatment with olanzapine was chorea in 27, behavioral problems in 8, or both in 6. The average dose was 10.4 mg/day (range 1.25-30 mg). The average duration of treatment was 20.9 months (range 3-59 months). Baseline chorea score was 9.4 Ϯ 4.9, and last observation chorea score was 6.8 Ϯ 5, a 27.5% reduction (P Ͻ 0.01). Mean weight gain was 3.9 kg (P Ͻ 0.05 Objective: To examine demographic and clinical factors associated with variability in age of onset in a heterogeneous sample of individuals with Huntington's disease (HD). Background: The importance of CAG repeat length in determining age of onset in HD has been well documented; however, considerable variability in phenotypic expression remains after controlling for repeat length, especially at the lower end of the repeat spectrum (i.e., 39 -43). Investigating CAG repeat length in an ethnically diverse sample could improve our prediction of HD onset, especially when combined with clinical and demographic information. Methods: 184 affected individuals, including 31 Hispanics, followed prospectively, were genotyped for CAG repeat length (M ϭ 45.6). Gender, ethnicity, education, affected parent, depression, and substance abuse were also examined as predictors of age of onset (M ϭ 41.9), using hierarchical multiple regres-sion. Potential ethnic differences were examined using one-way ANOVA.
POSTER 5
Results: In the entire cohort, CAG repeat length accounted for 54% of the variance in age of onset (P Ͻ 0.001), with the remaining factors each uniquely accounting for Ͻ1% of the variance. In individuals with CAG repeat length of Ͻ44 (n ϭ 77), however, CAG repeat length accounted for only 21% of the variance, with demographic and clinical variables accounting for an additional 12%. Despite comparable mean CAG repeat length and age of onset, the relationship between these two variables was much stronger in the Hispanic than in the Caucasian group (R 2 ϭ 0.61 vs 0.53). Dramatic ethnic differences emerged for individuals with repeat lengths of Ͻ44: CAG repeat length accounted for only 17% of the variance in age of onset for Caucasians, compared with 86% for Hispanics. Conclusions: The extreme variability in age of onset at the low end of the CAG repeat spectrum demonstrates the importance of identifying potential modifying factors and including an ethnically diverse sample in predictive models of HD.
POSTER 8 Five Years of Monitoring the Safety and Feasibility of PHAROS (Prospective Huntington At Risk Observational Study). E.P. Kayson and the Huntington Study Group PHAROS Investigators. University of Rochester Medical Center, USA.
Objective: PHAROS [Arch Neurol 2006; 63:991-996] aims to identify factors that affect the feasibility and safety of longterm trials in unaffected individuals who may carry the Huntington's disease (HD) gene. Methods: Protocol adherence, mental health, life events, and retention of participants were monitored from the first PHAROS enrollment in July 1999 and were analyzed without knowledge of HD (CAGn) gene status. Results: 1001 PHAROS participants, aged 41.3 Ϯ 7.3 years, were enrolled at 43 Huntington Study Group (HSG) research sites and were re-evaluated at ϳ9-month intervals over an average of 5 years of follow-up. As of May 2007, a total of 811 reported events of pre-specified interest involved 546 participants, including a 3.9% annual incidence of heightened suicide risk (five suicide attempts but no resulting deaths) and a 2.5% annual incidence of medical hospitalizations. In all, 215 subjects withdrew consent to participate; 48 (4.8%) withdrawals occurred in the initial year of the study. Withdrawal rates for the second, third, fourth, and fifth visits were 4.7%, 4.6%, 3.3%, and 4.5%, respectively. Of the 786 participants actively followed, 72% were seen within the past 12 months. Conclusions: Longitudinal research involving unaffected individuals at risk for HD appears to be safe and feasible over a 5-year period of observation. The average annual withdrawal rate in PHAROS stayed approximately constant over more than 5 years of follow-up. The design of long-term trials needs to consider the ongoing mental health of research participants and the pace of consent withdrawal, which might expectedly be less in interventional than in observational studies. Objective: To identify regional brain metabolic correlates of neuropsychological function in presymptomatic HD gene carriers (pHD). Background: Subtle cognitive and behavioral symptoms may emerge in pHD and may herald the transition to symptomatic disease. The regional brain correlates of early cognitive impairment in HD have not been well described. Methods: As part of an ongoing longitudinal progression study in 11 pHD subjects (age 48.1 Ϯ 10.6; CAG repeats ϭ 41.6 Ϯ 1.75), we performed comprehensive neuropsychological testing and [ 18 F]fluorodeoxyglucose (FDG) PET. Neuropsychological tests were consolidated into composite scores for attention, working memory, speed of processing, executive function, learning, retention, visual perception, visuomotor construction, fine motor dexterity, and mood. These scores were correlated with brain metabolism in the four regions of a pHD-specific metabolic brain network identified with FDG PET (striatum, anterior cingulate, ventrolateral thalamus, and cerebellum). Results: Anterior cingulate metabolism correlated with executive function (r ϭ 0.67; P ϭ 0.02) and fine motor dexterity (r ϭ 0.83; P ϭ 0.003). Striatal metabolism correlated with visuomotor construction (r ϭ 0.65; P ϭ 0.03). No other correlations were identified. Over the course of this 4-year progression study, four pHD subjects were diagnosed with HD; at baseline, these subjects exhibited significantly lower performance on tasks of executive function (P ϭ 0.01). Conclusions: Executive function may be abnormal in pHD, especially as pHD subjects near symptom onset. Reduced metabolism in anterior cingulate cortex may underlie early impairments in executive function. 18 F]FDG PET and MRI in both presymptomatic HD gene carriers (pHD) and symptomatic patients. It has been suggested that atrophy may contribute to hypometabolism observed in the striatum and the cortex. However, the degree to which brain atrophy accounts for declines in metabolism remains uncertain. In this study, we utilized an atrophy correction algorithm to localize abnormal metabolic changes in pHD subjects as part of a longitudinal study. Methods: We used PET/MRI brain scans from 12 pHD subjects (CAG length ϭ 42 Ϯ 2; age 47 Ϯ 11 years) at baseline and after 18 months. The correction of brain atrophy in each PET image was performed on a voxel basis using registered/ segmented MRI data and PET resolution information. Both images were then spatially normalized and separately compared with those from 11 gene-negative normal subjects (age 41 Ϯ 15 years) using statistical parametric mapping. We focused on the effect of brain atrophy on striatal metabolism in this preliminary analysis. Results: Before atrophy correction, the pHD gene carriers showed progressively significant hypometabolism in the striatum relative to the normal controls. The reduction in metabo-lism was bilateral and homogeneous in both caudate nucleus and putamen. After atrophy correction, striatal metabolism was normal at baseline but was slightly lower in the posterior putamen at 18 months. Discussion: Early hypometabolism in pHD is largely accounted for by atrophy. Nonetheless, our data suggest that neuronal dysfunction likely precedes atrophy as HD progresses. The atrophy correction algorithm described here may provide insights into the mechanisms underlying neurodegeneration in HD, and could aid in the development of an imaging biomarker for the disease. Objective: The purpose of this study was to evaluate whether the rate of change in neuropathological involvement was related to CAG repeat size. Methods: Medical records were evaluated for 259 postmortem Huntington's disease brains received from the Harvard Brain Tissue Resource Center at McLean Hospital in Belmont, MA. Information for ages at motor onset and death was used to determine duration of the disease. Each postmortem brain was graded using the Vonsattel method for evaluating the extent of neuropathological involvement. Brains were available only for grades 2, 3, and 4. HD CAG repeat length was determined for each case at the Center for Human Genetic Research at the Massachusetts General Hospital. Results and Conclusions: Controlling for duration of disease, for each unit increase in HD CAG repeat an increase of 0.07 units was observed for the neuropathological grade (P Ͻ0.001) at death. We compared the average grade for five repeat categories (40 -42, 43-44, 45-47, 48 -50 , and 50ϩ) within four duration groups: brief (Ͻ12 years), short (13-17 years), mid (18 -23 years), and long (24ϩ years). Those with shorter repeat sizes had a lower grade of pathological involvement than did those with larger repeat sizes. For example, in the "Mid" duration group, representing a person who died after 18 -23 years with HD, those with repeats of 40 to 42 had a mean grade of 2.81, whereas those with repeats of Ͼ50 units had a mean grade of 3.83. This indicates that persons with larger repeats had experienced a greater extent of neuropathological involvement than those with shorter repeats over the same time period leading to death. These findings support the hypothesis that the HD repeat size is a powerful determinant of the rate of change in neuropathological involvement. Background: Therapeutic neuroprotective trials in the "premanifest" population aimed at delaying the onset of manifest HD could potentially have a significant impact on this devastating disorder. Coenzyme Q10 (CoQ) has emerged as one of the leading therapeutic candidates for neuroprotection in manifest HD [Huntington Study Group, Neurology 2001; 57:397-404] . Although there are substantial data on the tolerability of CoQ at 600 mg/day in symptomatic HD, dose ranging studies suggest the possibility of decreased tolerability in otherwise healthy individuals at higher dosages. Proposal: We propose to study CoQ at dosages of 600 mg/day, 1200 mg/day, and 2400 mg/day to determine, in a population of expansion positive pre-manifest participants, the highest dosage that is tolerable, with the long term objective of developing future preventive therapeutic trials of CoQ at that dosage. We propose to establish the safety and tolerability of CoQ at dosages of 600 mg/day, 1200 mg/day and 2400 mg/day in a mutation positive pre-manifest population with the HD CAG repeat expansion, in the context of a randomized double-blind 20 week parallel-group trial. We propose to establish that CoQ is biologically active by assessing changes in serum CoQ levels, as well as 8-hydroxydeoxyguanosine (8OHdG) and 8-hydroxyguanosine (8OHrG) levels in the same trial. We will assess the relationships between serum levels of CoQ, biomarkers of oxidative stress, biomarkers of DNA repair mechanisms (OGG1), and dosage levels of CoQ. Discussion: The proposed trial is significant in that it will be the first study to evaluate a potential therapeutic agent in a population of individuals at 100% risk for developing a neurodegenerative illness, but who are not yet ill. It will allow us to select a dosage of CoQ for future definitive randomized placebo controlled trials in pre-manifest HD to delay or prevent onset of manifest HD, and will give us valuable information about the process and feasibility of such trials in pre-manifest participants. Unit has very high rates of enrollment and retention success. This is achieved by the application of number of strategies, including study promotion through AHDA, direct marketing to the HD community, and careful selection process. Successful retention is achieved by sensitive rapport building, support, regular communication, and personal relationships with participants by designated team member. Encouragement of value added activities during visit. The effective strategies utilized by the Academic Unit resulted in successful participation in PREDICT-HD (the highest recruiting center of the 32 centers) and thus contributes to the development of body of knowledge about HD for the benefit of current and future HD community members.
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POSTER 15 PREDICT-HD Family Participation in HSG Site 144.
O. Yastrubetskaya, A. Goh, J. Preston, and E. Chiu. The University of Melbourne, Australia.
Background: HD research is impossible without the dedicated support of participants and their families. Due to the low prevalence and incidence of HD in the population, recruitment is challenging. The PREDICT-HD study commenced in 2003 at the St George's site, operated by the Academic Unit. It is the leading recruitment site, with 99 potential participants screened and 76 enrolled (77%). Family members share the awareness of the research through 1) regular updates, telephone calls, and newsletters from the site; 2) letters of thanks and information sent to participants; 3) family communication; and 4) AHDA meetings and newsletters.
Methods:
We analyzed our PREDICT-HD cohort and familial relationships, determining the number of families with one participating member, families with multiple participating members, the number of first and second-degree relatives, of gene-positive and gene-negative participants, and the number of other family members who are eligible to participate in the study. Results and Discussion: Of 76 subjects, 30 (39%) are members of 12 families with more than one PREDICT-HD participant participating at our site. Family genograms and analysis of first-and second-degree relatives will be presented. The timeframe of enrollment of family members was highly variable-from months to years. Overall, family participation is high at our site, but the timeframe of enrollment was found to be highly variable. The high rate of family participation reflects a strong family commitment to HD research and has significantly contributed to the data.
Recruitment and retention strategies are necessary to maintain such high levels of family participation. 
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Background:
The frequency of genetic testing among individuals at risk for Huntington's disease (HD) is low, despite potential advantages to knowing one's HD gene status. Aim: To explore insurance-related barriers to genetic testing and to evaluate factors associated with the eventual pursuit of testing in a PHAROS, a longitudinal observational study of asymptomatic individuals at risk for HD [Arch Neurol 2006; 63:991-996] . Methods: We used PHAROS data to explore the reasons cited for lack of genetic testing at enrollment in the study. We also compared the pre-testing survey responses of those who pursued testing and those who did not. Results: All 1001 individuals enrolled in PHAROS had some data available at enrollment. At baseline, 54% of those enrolled report that fear of insurance loss was either a "somewhat" or "extremely" important factor in their decision not to pursue genetic testing thus far. Only 13% ranked this factor as an "extremely unimportant" barrier to testing. Relative to individuals who did not pursue testing, those who did viewed insurance loss as an initial barrier to testing (P Ͻ 0.01). Individuals who were eventually tested were also significantly more likely to have paid out of pocket for insurance costs, to avoid revealing their genetic risk (20% vs 3%, P Ͻ 0.001). Items paid for out of pocket were principally baseline screening for neurological problems and for pre-implantation genetic diagnosis. Conclusions: Fear of insurance loss appears to be a significant barrier to genetic testing for individuals at risk for HD. Paying health care expenses out of pocket to avoid revealing risk status is a reality for a significant fraction of people at risk. Group, Mov Disord 1996; 11:136-142] , and more recently has been used extensively in pre-diagnosis and early HD. We used meta-analysis to examine the relative sensitivity of each of the UHDRS cognitive tasks in these earlier phases of HD.
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Methods and Results:
First, we conducted a systematic review of the literature published since 1993 (advent of PCR genetic analysis) to identify 38 studies that 1) compared test performance in pre-diagnosis or early HD (Ͻ7 years since diagnosis) longitudinally over time or cross-sectionally to a gene-negative control group and 2) contained sufficient data on a UHDRS cognitive test to compute an effect size (ES). Using metaanalysis to estimate ESs (Hedge's g for cross-sectional studies and standard paired difference for longitudinal studies), the largest ESs were found in cross-sectional studies of early HD (g ranging from Ϫ1.04 to Ϫ1.58; P Ͻ 0.001 across all tests). In contrast, cross-sectional studies in pre-diagnosis HD indicated statistically significant ESs only for the Word and Color conditions of the Stroop (g ϭ Ϫ0.48, P Ͻ 0.01, and g ϭ Ϫ0.49, P ϭ 0.01, respectively) and Letter Fluency (g ϭ Ϫ0.38; P ϭ 0.02), with larger ESs being associated with increasing proximity to onset. Background: The PREDICT-HD study is a prospective, longitudinal study of cognitive, psychiatric, motor, and brain changes in the pre-manifest stages of Huntington's disease (HD). In contrast to prior reports of a disgust-specific emotion recognition deficit in HD, the baseline data from the PREDICT-HD study indicated that CAG-expanded individ- Methods: In the current study, we examined the same computerized facial emotion recognition task across a 2-year longitudinal interval in 407 participants (361 preHD and 46 controls). Logistic regression with repeated measures was used to examine associations between 2-year change in emotion recognition performance and measures of estimated proximity to clinical diagnosis (based on CAG repeat length and current age), striatal volumes, and motor signs of HD. Results and Discussion: Overall, the longitudinal findings were consistent with our cross-sectional results. Two-year declines in recognition of anger, disgust, fear, and sadness (but not happiness and surprise) were associated with estimated proximity to clinical diagnosis. Baseline striatal volumes were predictive of the amount of 2-year decline in recognition of happy and fearful faces, and 2-year change in striatal volume was associated only with the amount of decline in fear recognition. Interestingly, we found no association between baseline motor signs of HD, characterized by the UHDRS confidence level ratings, and 2-year change on the emotion recognition task. Findings confirm our cross-sectional conclusion that recognition of all negative emotions declines early in the disease process in HD and, furthermore, reveal that the rate of decline is fastest for those estimated to be closest to clinical onset. 
Introduction:
The pathoetiology of Huntington's disease (HD) is known classically as involving primarily the striatum. Recent studies, however, have emphasized the involvement of additional brain regions, such as the cerebral cortex and white matter. This study was designed to assess the structure (vol-ume) of the cerebral cortex and white matter in a large group of subjects with preclinical HD. Methods: A total of 612 subjects had MRI scans, collected from the multicenter PREDICT-HD study; 128 gene-negative subjects served as controls for 484 gene-expanded subjects. The gene-expanded subjects were divided into 30 with recent diagnosis and three prognostic groups not yet diagnosed: far from, midway to, and near HD onset (based on CAG length and age). Volumes of cerebral cortex and white matter were expressed as ratios to intracranial volume. Age, gender, and scanner-to-scanner variation were statistically controlled. Results: Cortical volumes were slightly lower than the control group for all three preHD groups. Although statistically significant, differences were subtle and did not show substantial change among the far, mid, and near groups. Furthermore, no clear change was shown for those recently diagnosed. In contrast, cerebral white matter volume was robustly different, with the far from onset preHD group having smaller volumes relative to the comparison group (P ϭ 0.0006), and with progressively lower white matter volumes seen in subsequent groups: far Ͼ midway Ͼ near onset Ͼ recently diagnosed. Discussion: In preclinical HD subjects, white matter volumes are significantly decreased, even far from disease onset. In contrast, global cortical volume changes are relatively small. Measurable progression of smaller white matter volume spanning many years from diagnosis through recent diagnosis supports the notion that these changes could potentially be utilized as a biomarker for disease progression. Our HD specialty clinics have followed more than 40 individuals with onset of HD at age 55 or older. This review presents a compilation of these cases seeking unique characteristics of this subpopulation. Symptoms at onset, delay in diagnosis or misdiagnosis, CAG repeat expansion size, whether the older person is the first in the family to be diagnosed with HD, social issues, course of the disease, and co-morbidity (including Alzheimer's disease) are tabulated. Implications for genetic counseling are discussed. Objective: Review cause and place of death in Huntington's disease (HD) patients followed up in the community. Background: HD has a prolonged course of up to 17 years, often longer. Death is usually in an institution when hospitalbased clinic follow-up may be impractical. The number of patients known to the HD service in New South Wales is similar to the estimated prevalence in the state of New South Wales. There is a need for more information about the place and cause of death to allow improved chronic and palliative care. Methods: Review of confidential data base and service records January 1996 -June 2005 for patients known to the comprehensive multidisciplinary HD service based at Westmead Hospital in Sydney that allows contact with and follow-up for most patients in the state of New South Wales over the course of HD. Demographic data and place and cause of death were analyzed. Results: Of 450 HD patients followed over almost 10 years, 150 died, most in an institution. Mean life span was 59 years (range 25-90). 128 resided in institutions. Cause of death was known in 98. Inanition and gradual deterioration were most frequent, accounting for 43 deaths. Death resulted from pneumonia in 23. Head injury was the cause in 8. No death was due to choking. There was a low rate of 4 suicides. Discussion: This population, followed in the community until death, was equivalent in number to the known estimated prevalence for HD in the state of NSW and may therefore more accurately reflect the causes of death in HD. The low suicide rate of 1% may be attributable to the close monitoring of this group in the HD clinic as well as within the community. Objective: To describe the symptoms of the last year of life for Huntington's disease patients residing in a skilled nursing facility. Methods: This study was a chart review of 11 Huntington's disease patients who died at Terence Cardinal Cooke Health Care Center between 1996 and 2003. The reviews were conducted after death, and chart selection was based on chart availability. The following information was reviewed: progress notes and physician's orders for the last year of life, intake assessments, advance directives, genetic testing reports, and demographic data. Results: The mean age at admission was 44.8 years, and the mean age at death was 51.2 years. The mean age of onset was 39.4 years, and the mean disease duration was 12.8 years. The number of unique prescriptions was 13.82, and the number of medications decreased exponentially as the length of stay increased. PEG tube replacement was the most frequent reason for hospital transfer. The average number of hospitalizations was 4.1. and the number of hospitalizations was inversely correlated with length of stay. As length of stay increased, difference between maximum and minimum weight decreased significantly. Seven of the 11 patients had recorded decreases in net annual weight change. Nine patients were on feeding tubes, four were independently mobile (during at least part of the last year of life), and five retained verbal capacity. Seven patients had at least one advance directive in place. Four patients had suspected diagnosis or confirmed diagnosis of aspiration pneumonia at death. Other recorded circumstances of death included cardiac arrest, cancer, found unresponsive/no pulse, and lethargy.
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Conclusions:
The last year of life in HD is idiosyncratic, defying accurate prognostication. Although most patients will become averbal and immobile in the end stages, death can occur unexpectedly in higher functioning residents, which complicates discussions relating to terminal care. Objective: The purpose of this series of studies was to systematically investigate the factors that enhance and compromise the lives of Huntington's disease (HD) spousal carers by utilizing the theoretical construct of quality of life (QoL). Methods and Results: Three exploratory studies provided evidence that spousal carers of HD patients have specific difficulties in maintaining their QoL while continuing in a primary care-giving role. Study 1 provided preliminary evidence that spousal carers of HD patients and health care professionals would value a disease-specific QoL scale that could be used to evaluate the spousal carer's objective and subjective QoL. Study 2 established that spousal carers of HD patients often experience loneliness, a need to escape, and a unique sense of loss, while trying to adequately care for their loved ones and maintain some form of QoL for themselves. Study 3 provided further evidence that QoL is compromised in many ways and is an issue for HD carers. The carers in this study often neglected their own needs as the care-giving role and disease processes 'took over' their lives as well as the life of the HD-affected spouse.
BASIC SCIENCE/EXPERIMENTAL THERAPEUTICS
The findings of these three studies prepared the way for the development of a disease-specific QoL measure for spousal carers of HD patients. Validation of the Huntington's Disease Quality of Life Battery for Carers (HDQoL-C) was performed in study 4. The HDQoL-C was established as a multidimensional and psychometrically sound disease-specific and subjective QoL assessment tool that incorporates the individual's physical health, psychological state, level of independence, social relationships, personal beliefs, and relationship to salient features of the environment. It demonstrates good internal consistency, test-retest reliability, and face validity. Although it was developed with a UK population, we intend to validate the HDQoL-C for use with a North American population in order to implement and assess therapeutic interventions. Background: The UHDRS99 scales for Huntington's disease motor signs and diagnostic confidence constitute nearly universal research standards. Despite their great utility, analyses from the PREDICT-HD study suggest substantial variation in scale calibration among expert raters. Improved standardization would yield improved statistical power and replicability of clinical HD studies, including therapeutic trials. Methods: We approximated differences between current scale use and ideal standardization by fitting Cox proportional hazard models predicting time until diagnosis (by UHDRS diagnostic confidence rating ϭ 4) as a function of either baseline UHDRS total motor score or diagnostic confidence rating. We fit these models with and without a random ("frailty") effect for variability among motor-raters in their propensity to assign new diagnoses. If the raters' calibrations of diagnosis, lesser diagnostic confidence levels, and motor scores are linked, then adjustment for this rater effect approximates the potential impact of ideal standardization on the prognostic value of baseline motor ratings and confidence levels. Results: Of 551 gene-expanded PREDICT participants, 68 received prospective diagnoses. Median follow-up was 2 years. Preliminary analyses showed substantial variability in motor scores at the time of diagnosis among 47 raters. Random interrater variability was highly significant in proportional hazard models based on either baseline motor score or diagnostic confidence (P Ͻ 0.0001 in each case). Motor scores and diagnostic confidence were substantially more predictive in the models adjusted for inter-rater variability. The proportional hazard (PH) effect of a 5-point motor scale difference was 42% stronger in the rater-adjusted model. PH effects for initial diagnostic confidence increased between 14% (confidence level 1 vs 0) and 86% (confidence level 3 vs 0). Conclusions: Although these analyses cannot entirely clarify the relative importance of motor score versus diagnostic confidence standardization, they highlight the potential value of improved, systematic rater training for both scales. Background: In order to prepare for clinical trials in Huntington's disease (HD), there is a need to identify sensitive markers that reliably track disease progression during the earliest phases of the disease (prior to clinical diagnosis; pre-HD). Methods: In the PREDICT-HD study, we have identified the University of Pennsylvania Smell Identification Test (UPSIT) as one of several sensitive markers. The UPSIT, which takes up to 20 minutes administration time, requires participants to identify 40 different scratch-and-sniff smells (10 items in each of 4 books) by matching the smell to one of four possible choices. Despite the UPSIT's demonstrated cross-sectional and longitudinal sensitivity in pre-HD individuals, its lengthy administration time limits its utility in interventional trials. To examine the possibility of reducing administration time by reducing the number of items, we computed 2-year longitudinal effect sizes for pre-HD participants and controls for each of the four books, for two published alternative books (one 10-item and one 12-item book), and for pairs of these books. We also examined the ability of each of these test books and for pairs of test books to predict class membership (pre-HD; near, mid, and far from clinical diagnosis; and controls). Results: Although the general patterns of effect sizes were consistent across books, the combination of books 1 and 3 yielded effect sizes that were most similar in magnitude to the effect sizes for the full four-book test. Furthermore, all books yielded similar group classification accuracy. Conclusions: On the basis of our findings, we recommend using a 20-item abbreviated version of the UPSIT (books 1 and 3) in clinical trials with pre-HD participants. This abbreviated version will substantially shorten administration time without sacrificing the overall sensitivity of this test to subtle disease progression in pre-HD.
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